Rovin Capital UT ADV Acquires 497 Shares of Danaher Corporation $DHR

Rovin Capital UT ADV boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 22.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,740 shares of the conglomerate’s stock after purchasing an additional 497 shares during the quarter. Rovin Capital UT ADV’s holdings in Danaher were worth $541,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the last quarter. Invesco Ltd. lifted its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after purchasing an additional 163,332 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Danaher during the 1st quarter valued at about $833,941,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

DHR stock opened at $210.97 on Friday. The stock has a market cap of $149.02 billion, a PE ratio of 43.50, a P/E/G ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company has a 50-day moving average price of $203.94 and a 200 day moving average price of $200.14. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the company posted $1.71 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Redburn Partners set a $220.00 price objective on Danaher in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft increased their target price on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Bank of America decreased their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.